Superior Therapeutic Antibody Candidates Enabled by Integrated In Vivo Discovery Workflows

Identifying therapeutic antibody candidates with broad epitope coverage, strong developability, and translatability remains a key challenge in biologics discovery. In this talk, Mosaic presents a case study leveraging Atlas™ Full Human Diversity (FHD) mice immunized with the model antigen CD22. Antibody candidates were selected to maximize sequence diversity while systematically eliminating sequence liabilities, followed by recombinant expression to confirm single B-cell screening results. This integrated workflow yielded antibodies spanning a broad range of affinities, with favorable developability profiles and diverse epitope coverage. Collectively, these findings demonstrate that Atlas™ FHD mice enable the efficient generation of high-quality candidates suitable for therapeutic discovery.